Dalfampridine Tablet, Film Coated, Extended Release
Product Images NDC 0591-2533

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 0591-2533). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

2 (Image 1)

2 (Image 1)
This appears to be a medical formula used for calculating creatinine clearance (CrCl), a measure of kidney function. The formula uses the age and weight of the patient, as well as the serum creatinine level, to determine the estimated glomerular filtration rate (eGFR). The text provides the equations for this calculation, which involve multiplying the patient's age (in years) minus 140 by their weight (in kg), and then multiplying the serum creatinine measurement (in mg/dL) by 72. The resulting products are then divided by 1,000, and multiplied together to give an estimated creatinine clearance value in ml/min.*
FDA Label Image

Chemical Structure (Image 2)

Chemical Structure (Image 2)
FDA Label Image

Figure 1 (Image 3)

Figure 1 (Image 3)
This appears to be a graph or chart showing the results of a clinical trial comparing the effects of placebo versus 10mg of Dalfampridine Extended-release tablets twice a day on walking speed in patients. The percentage of patients achieving certain levels of improvement in walking speed is displayed on the y-axis, while the x-axis shows different thresholds of improvement. P-values are provided for each threshold, indicating statistical significance of the results.*
FDA Label Image

Figure2 (Image 4)

Figure2 (Image 4)
This text seems to be a statistical data about patients taking Dalfampridine Extended release Tablets compared to patients taking a placebo. The data shows an increase in walking speed from the baseline for patients taking the tablets. The percentages indicate the average increase in walking speed and the P-values obtained at different thresholds for comparison.*
FDA Label Image

New (Image 5)

New (Image 5)
This is a description of a medication with the brand name Teva. The medication comes in the form of film-coated tablets, and each tablet contains 10mg of Dalfampridine. The tablets are sold in containers with child-resistant closures and should be kept out of reach of children. The package insert provides dosage information, and it is recommended that the tablets are taken whole and not divided, crushed, chewed or dissolved. The medication should be stored at 20°10 to 25°C (68°to 77°F) and is manufactured for Teva Pharmaceuticals USA, Inc. The package contains 60 tablets, and there is a serialization coding area included. It is only available with a prescription and comes with a guide for each patient.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.